Royalty Pharma (RPRX) revenue: $2.4B
Royalty Pharma reported $2.4B of revenue for the year ended Dec 31, 2025, up 5.1% from $2.3B a year earlier.
From Royalty Pharma's filings with the SEC · Read the filing · RPRX stock page
Royalty Pharma revenue by year
#1,091 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $2.4B | +5% |
| Dec 31, 2024 | $2.3B | -4% |
| Dec 31, 2023 | $2.4B | +5% |
| Dec 31, 2022 | $2.2B | -2% |
| Dec 31, 2021 | $2.3B | – |
Revenue of similar companies
Companies in the same industry as Royalty Pharma, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Alnylam Pharmaceuticals | $3.7B | Dec 31, 2025 |
| Biomarin Pharmaceutical | $3.2B | Dec 31, 2025 |
| United Therapeutics | $3.2B | Dec 31, 2025 |
| Amneal Pharmaceuticals | $3B | Dec 31, 2025 |
| Royalty Pharma | $2.4B | Dec 31, 2025 |
| Sarepta Therapeutics | $2.2B | Dec 31, 2025 |
| PTC Therapeutics | $1.7B | Dec 31, 2025 |
Questions and answers
What is Royalty Pharma's revenue?
Royalty Pharma reported $2.4B of revenue for the year ended Dec 31, 2025, up 5.1% from $2.3B a year earlier.
Numbers as reported in Royalty Pharma's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology